• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Fol­low­ing BeiGene, Zai Lab changes au­di­tors amidst SEC threat of delist­ing

4 years ago
Financing
China

Sanofi of­floads two late-stage drugs to vir­tu­al­ly un­known neu­ro and psy­che­del­ic biotech

4 years ago
Deals
R&D

FDA signs off on Gilead­'s mas­sive new CAR-T man­u­fac­tur­ing site in Mary­land

4 years ago
Cell/Gene Tx
Manufacturing

Ora­sis will ship its Vuity eye drop com­peti­tor to the FDA lat­er this year with two PhI­II wins

4 years ago
R&D

Drugs con­tain­ing nano­ma­te­ri­als: FDA fi­nal­izes 2017 guid­ance with sev­er­al changes

4 years ago
FDA+

Pre­scrip­tion drug use surged last year — but IQVIA does­n't ex­pect that to last

4 years ago
Pharma

Reify Health thinks clin­i­cal tri­als can be rep­re­sen­ta­tive by 2030 — and it’s se­cured the cap­i­tal to help part­ners ...

4 years ago
Financing
Pharma

Syn­thet­ic bi­ol­o­gy biotech nets three-hit com­bo in new fi­nanc­ing, Bris­tol My­ers deal and first CSO

4 years ago
Financing

As­traZeneca show­cas­es 83% risk re­duc­tion for long-act­ing Covid-19 an­ti­body at 6-month analy­sis

4 years ago
Coronavirus

Still strug­gling to get an EUA, No­vavax paints ear­ly rosy pic­ture of com­bo Covid-19/flu vac­cine

4 years ago
R&D
Coronavirus

GAO: FDA work­ers feared re­tal­i­a­tion for com­ing clean on po­lit­i­cal in­ter­fer­ence be­hind sci­en­tif­ic de­ci­sions

4 years ago
FDA+

Mar­ket­ingRx Matchup: What do peo­ple think about Rex­ul­ti ver­sus Trin­tel­lix de­pres­sion TV ads? It’s close.

4 years ago
Pharma
Marketing

GSK man­u­fac­tur­ing work­ers vote to strike over pay dis­pute as Walm­s­ley promis­es com­pa­ny growth

4 years ago
Pharma

In Frank Clyburn's ab­sence, Mer­ck taps sea­soned vet­er­an to run in­ter­na­tion­al Hu­man Health busi­ness

4 years ago
People
Pharma

Ther­mo Fish­er opens site in Utah as part of sin­gle-use spend­ing spree

4 years ago
Pharma
Manufacturing

New T cell im­mune re­sponse dis­cov­ery points to 'out-of-box' can­cer ther­a­py op­tions

4 years ago
Discovery
Cell/Gene Tx

No­var­tis of­fers $25M more in med­ical aid to Ukraine while sus­pend­ing sev­er­al ac­tiv­i­ties in Rus­sia

4 years ago
Pharma

Sanofi breaks ground on car­bon-neu­tral, mul­ti-vac­cine site in Sin­ga­pore

4 years ago
Pharma
Manufacturing

Supreme Court calls on top gov­ern­ment lawyer to weigh PC­SK9 patent ap­peal

4 years ago
Pharma
Law

Ogilvy Health’s new ex­ec­u­tive cre­ative di­rec­tor brings big-name con­sumer ex­pe­ri­ence to ‘less cyn­i­cal’ health ...

4 years ago
Pharma
Marketing

For­mer IQVIA em­ploy­ees push for class ac­tion law­suit, al­leg­ing mis­man­age­ment of 401(k) plan

4 years ago
Pharma
Law

Up­dat­ed: How Gilead, Re­gen­eron and Genen­tech used po­lit­i­cal con­nec­tions to hur­ry their Covid-19 drugs

4 years ago
FDA+

Arc­turus slides on PhI­II Covid-19 vac­cine da­ta, sig­ni­fy­ing the strug­gle in pro­duc­ing fol­low-up shots

4 years ago
R&D
Coronavirus

With boost­ed biode­fense work, Heat Bio ices its name in fa­vor of NightHawk

4 years ago
Pharma
Cell/Gene Tx
First page Previous page 536537538539540541542 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times